MAPT and tauopathy: In future studies, a detailed behavioural analysis of MAPT-ASO2-treated 5×FAD mice or humanized tauopathy mice [95] needs to be conducted to assess the effects of MAPT-ASO2 administration on cognitive parameters altered by amyloid and tau pathologies.